Mechanism of Intestinal Flora in Hepatic Fibrosis and Its Therapeutic Progress
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v7i2.5323
Abstract
Hepatic fibrosis is a common pathological process that progresses to cirrhosis in various chronic liver diseases, and there is a lack of effective treatment at present. In recent years, intensive studies on the intestinal-liver axis theory have shown that intestinal dysbiosis plays a key role in the development of liver fibrosis. This paper systematically reviews the mechanisms of intestinal flora in liver fibrosis, including intestinal barrier dysfunction, translocation of pathogen-related molecular patterns, regulation of flora metabolites, and imbalance of immune-metabolic network. On this basis, therapeutic strategies targeting intestinal flora are summarized, including emerging therapies such as probiotics/synbiotics, fecal flora transplantation, and bile acid modulators. In-depth understanding of the relationship between intestinal flora and liver fibrosis is expected to provide new ideas for the prevention and treatment of liver fibrosis.
Keywords
intestinal flora; liver fibrosis; intestinal-hepatic axis; pyroptosis; Fecal bacteria transplantation
Full Text
PDF - Viewed/Downloaded: 3 TimesReferences
[1] Che Y, et al. Gut Microbiota Dysbiosis and LPS/NLRP3/GSDMD Pyroptosis Drive Hepatic Fibrosis: Therapeutic Potential of a Synbiotic Intervention. Probiotics Antimicrob Proteins. 2025.
[2] Sun YD, et al. Gut-liver axis drives the triple mechanism of liver inflammation-carcinogenesis: Microbial-immune-metabolic network. Biochim Biophys Acta Rev Cancer. 2026;1881(2):189563.
[3] Anis MA, Shahid Y, Majeed AA, Abid S. Microbiome and gut-liver interactions: From mechanisms to therapies. World J Gastroenterol. 2025;31(40):111409.
[4] Wu Huaying, Yang Qi, Yu Fei. Research progress on the mechanism and treatment of intestinal flora on metabolism-related fatty liver disease. The homology of medicine and food. 2025.
[5] Li Y, et al. The gut microbiota-bile acid axis in cholestatic liver disease. Mol Med. 2024;30:104.
[6] Duarte L, Magne F, Gotteland M. Gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease. Curr Opin Clin Nutr Metab Care. 2025;28(4):307-315.
[7] Kwan SY, Gonzales KA, Jamal MA, et al. Protection Against Fibrosis by a Bacterial Consortium in Metabolic Dysfunction-Associated Steatohepatitis and the Role of Amino Acid Metabolism. Gut Microbes. 2024;16(1):2399260.
[8] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577.
[9] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151-166.
[10] Tilg H, Adolph TE, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Cell Host Microbe. 2022;30(8):1051-1066.
[2] Sun YD, et al. Gut-liver axis drives the triple mechanism of liver inflammation-carcinogenesis: Microbial-immune-metabolic network. Biochim Biophys Acta Rev Cancer. 2026;1881(2):189563.
[3] Anis MA, Shahid Y, Majeed AA, Abid S. Microbiome and gut-liver interactions: From mechanisms to therapies. World J Gastroenterol. 2025;31(40):111409.
[4] Wu Huaying, Yang Qi, Yu Fei. Research progress on the mechanism and treatment of intestinal flora on metabolism-related fatty liver disease. The homology of medicine and food. 2025.
[5] Li Y, et al. The gut microbiota-bile acid axis in cholestatic liver disease. Mol Med. 2024;30:104.
[6] Duarte L, Magne F, Gotteland M. Gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease. Curr Opin Clin Nutr Metab Care. 2025;28(4):307-315.
[7] Kwan SY, Gonzales KA, Jamal MA, et al. Protection Against Fibrosis by a Bacterial Consortium in Metabolic Dysfunction-Associated Steatohepatitis and the Role of Amino Acid Metabolism. Gut Microbes. 2024;16(1):2399260.
[8] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577.
[9] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151-166.
[10] Tilg H, Adolph TE, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Cell Host Microbe. 2022;30(8):1051-1066.
Copyright © 2026 Jiahe Li, Jianmei Hao
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License